Friday, October 16, 2026

Lumber Bullish Momentum: 0.31% Up Since The Last Session

ViaNews Editorial Team

January 5, 2021

Lumber Bullish Momentum: 0.31% Up Since The Last Session

Lumber is currently on bullish momentum. At 16:11 EST on Tuesday, 5 January, Lumber is at $879.50 and 0.31% up since the last session's close.

Lumber Range

Lumber is 26.729% up from its last session low of $694.00 and 17.439% up from its last session high of $748.90.

Lumber is 0.51% up from its last three sessions higher value of $875.00 and is 26.73% up from its last three sessions lower value of $694.00.

Lumber is 2.33% down from its last seven sessions higher value of $900.50 and is 26.73% up from its last seven sessions lower value of $694.00.

Lumber is 2.33% down from its last month's higher value of $900.50 and is 38.94% up from its last month's lower value of $633.00.

Volatility

Lumber's last day, last week, and last month's average volatility was a positive 0.42%, a negative 6.41%, and a negative 0.01%, respectively.

Lumber's last day, last week, and last month's high and low average amplitude percentage was 7.91%, 4.94%, and 4.20%, respectively.

Last news about Lumber

US LBM acquires gilcrest/jewett lumber company. According to Business Insider on Monday, 4 January, "US LBM, a leading distributor of specialty building materials in the United States, has acquired Gilcrest/Jewett Lumber Company, a building products dealer and manufacturer with five locations in Iowa."

Lumber prices have increased worldwide in the second half of 2020 with US prices almost doubling. According to Business Insider on Tuesday, 5 January, "According to the Japan Lumber Journal, the most significant changes from September 2019 to September 2020 were an increase of Canadian hemlock prices by 15% (in Yen terms) and the decrease in European whitewood prices by about 13%."

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com